PharmiWeb

Auto-Injectors Market: A Transformative Force in Drug Delivery and Healthcare

The global auto-injectors market is rapidly evolving, emerging as one of the most dynamic segments of medical devices and pharmaceutical delivery systems. According to a FutureWise Research analysis, ...

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector

SteQeyma™ 45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, ...

Celltrion receives positive CHMP Opinion for SteQeyma(TM) (ustekinumab biosimilar) autoinjector

Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma (TM), a ...

Here’s What Analysts Think About Halozyme Therapeutics (HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable stocks with good earnings growth for 2026. Halozyme ...
Pharmabiz

US FDA grants 510(k) marketing clearance to Zephyrus Innovations’ VaporShield CSTD

US FDA grants 510(k) marketing clearance to Zephyrus Innovations’ VaporShield CSTD: Vancouver, BC Wednesday, December 17, 2025, 14:00 Hrs [IST] Zephyrus Innovations (Zephyrus), ...
Le Lézard

Liraglutide and Semaglutide Global Strategic Business Analysis Report 2025-2030: Regulatory Pipeline for Pediatric and Adolescents With Obesity Creates Long-Term Market ...

The "Liraglutide and Semaglutide - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Liraglutide and Semaglutide was valued at US$17.1 ...
The Malaysian Reserve

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet’s Disease Published in Rheumatology (Oxford)

Study results support advancing SGX945 in this difficult-to-treat orphan diseaseResults suggest potential durability of response for maintenance ...

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with ...

FUROSCIX is a registered trademark of scPharmaceuticals, a wholly owned subsidiary of MannKind Corporation. MANNKIND is a registered trademark of MannKind Corporation.

SOLIGENIX, INC.: Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

Study results support advancing SGX945 in this difficult-to-treat orphan disease Results suggest potential durability of response for maintenance therapy PRINCETON, N.J., Dec. 18, 2025 ...